Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.99
+0.01 (0.04%)
Dec 5, 2025, 4:00 PM EST - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Pacira BioSciences stock ranges from a low of $18 to a high of $65. The average analyst price target of $33.83 forecasts a 41.02% increase in the stock price over the next year.
Price Target: $33.83 (+41.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +58.40% | Nov 17, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +16.72% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Maintains $32 → $30 | Strong Buy | Maintains | $32 → $30 | +25.05% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +33.39% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $48 → $65 | Strong Buy | Maintains | $48 → $65 | +170.95% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
744.73M
from 700.97M
Increased by 6.24%
Revenue Next Year
815.73M
from 744.73M
Increased by 9.53%
EPS This Year
3.02
from -2.15
EPS Next Year
3.44
from 3.02
Increased by 13.96%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 769.3M | 871.5M | ||||
| Avg | 744.7M | 815.7M | ||||
| Low | 710.2M | 759.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 9.8% | 17.0% | ||||
| Avg | 6.2% | 9.5% | ||||
| Low | 1.3% | 2.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.20 | 3.79 | ||||
| Avg | 3.02 | 3.44 | ||||
| Low | 2.81 | 3.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 25.6% | ||||
| Avg | - | 14.0% | ||||
| Low | - | 0.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.